Melatonin for Treatment of Delirium in Critically Ill Adult Patients
DeliriumThe purpose of this study is to determine the feasibility of conducting a randomized controlled trial (RCT) with melatonin for treatment of delirium in critically ill adult patients. From a feasibility perspective, the investigators believe that the proposed design will achieve the minimum enrollment rate necessary to conduct a future RCT on a larger scale.
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
18 and up
Participation Criteria
Inclusion Criteria:
* Patients aged 18 years or older admitted to the intensive care unit;
* Anticipated ICU stay \> 48 hours;
* ICDSC score greater than or equal to 4 for a maximum of 48 hours prior to randomization.
Exclusion Criteria:
* Known allergy or hypersensitivity to melatonin or to ingredients in ORA-BLEND SF®;
* Use of melatonin within 24 hours prior to randomization;
* Presence of severe structural brain injury (intracranial hemorrhage or traumatic brain injury), severe major neurocognitive disorder, advanced neurodegenerative disease or hepatic encephalopathy;
* Diagnosis of schizophrenia, bipolar affective disorder, psychotic depression, uremic encephalopathy or alcohol withdrawal;
* Presence of active seizures, coma, aphasia or severe intellectual disability;
* Limited short-term vital prognosis;
* Diagnosis of delirium prior to ICU admission;
* Pregnancy or breastfeeding;
* Absolute contraindication to receive enteral medication;
* Inability to understand or speak English or French;
* Total blindness.
Study Location
Hopital Maisonneuve-Rosemont
Hopital Maisonneuve-RosemontMontréal, Quebec
Canada
Contact Study Team
Marianne Leblanc, Pharm.D.
Winnie Tran, Pharm.D.
Katerine Chalifoux, Pharm.D.
Aryane Roy, B.Pharm.
Mounia Louerguioui, Pharm.D.
Johannie Beaucage-Charron, Pharm.D., M.Sc.
Patricia Poirier, Pharm.D.
- Study Sponsored By
- Ciusss de L'Est de l'Île de Montréal
- Participants Required
- More Information
- Study ID:
NCT05713877